000142103 001__ 142103
000142103 005__ 20240229105144.0
000142103 0247_ $$2doi$$a10.1093/neuonc/noy073
000142103 0247_ $$2pmid$$apmid:29733378
000142103 0247_ $$2pmc$$apmc:PMC6231210
000142103 0247_ $$2ISSN$$a1522-8517
000142103 0247_ $$2ISSN$$a1523-5866
000142103 0247_ $$2altmetric$$aaltmetric:40718622
000142103 037__ $$aDKFZ-2018-02333
000142103 041__ $$aeng
000142103 082__ $$a610
000142103 1001_ $$0P:(DE-He78)c6e31fb8f19e185e254174554a0cccfc$$aPaech, Daniel$$b0$$eFirst author$$udkfz
000142103 245__ $$aAssessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T.
000142103 260__ $$aOxford$$bOxford Univ. Press$$c2018
000142103 3367_ $$2DRIVER$$aarticle
000142103 3367_ $$2DataCite$$aOutput Types/Journal article
000142103 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1550750828_27382
000142103 3367_ $$2BibTeX$$aARTICLE
000142103 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142103 3367_ $$00$$2EndNote$$aJournal Article
000142103 520__ $$aEarly identification of prognostic superior characteristics in glioma patients such as isocitrate dehydrogenase (IDH) mutation and O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status is of great clinical importance. The study purpose was to investigate the non-invasive predictability of IDH mutation status, MGMT promoter methylation, and differentiation of low-grade versus high-grade glioma (LGG vs HGG) in newly diagnosed patients employing relaxation-compensated multipool chemical exchange saturation transfer (CEST) MRI at 7.0 Tesla.Thirty-one patients with newly diagnosed glioma were included in this prospective study. CEST MRI was performed at a 7T whole-body scanner. Nuclear Overhauser effect (NOE) and isolated amide proton transfer (APT; downfield NOE-suppressed APT = dns-APT) CEST signals (mean value and 90th signal percentile) were quantitatively investigated in the whole tumor area with regard to predictability of IDH mutation, MGMT promoter methylation status, and differentiation of LGG versus HGG. Statistics were performed using receiver operating characteristic (ROC) and area under the curve (AUC) analysis. Results were compared with advanced MRI methods (apparent diffusion coefficient and relative cerebral blood volume ROC/AUC analysis) obtained at 3T.dns-APT CEST yielded highest AUCs in IDH mutation status prediction (dns-APTmean = 91.84%, P < 0.01; dns-APT90 = 97.96%, P < 0.001). Furthermore, dns-APT metrics enabled significant differentiation of LGG versus HGG (AUC: dns-APTmean = 0.78, P < 0.05; dns-APT90 = 0.83, P < 0.05). There was no significant difference regarding MGMT promoter methylation status at any contrast (P > 0.05).Relaxation-compensated multipool CEST MRI, particularly dns-APT imaging, enabled prediction of IDH mutation status and differentiation of LGG versus HGG and should therefore be considered as a non-invasive MR biomarker in the diagnostic workup.
000142103 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000142103 588__ $$aDataset connected to CrossRef, PubMed,
000142103 7001_ $$0P:(DE-He78)98b696ed60c17f4ddd0da9fdc20a2492$$aWindschuh, Johannes$$b1$$udkfz
000142103 7001_ $$0P:(DE-He78)7c89f57d41cbe565e6154bf1997b9178$$aOberhollenzer, Johanna$$b2$$udkfz
000142103 7001_ $$0P:(DE-HGF)0$$aDreher, Constantin$$b3
000142103 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b4$$udkfz
000142103 7001_ $$0P:(DE-He78)65fe7a46247e2ac4b15f194631c56cd1$$aMeissner, Jan-Eric$$b5$$udkfz
000142103 7001_ $$0P:(DE-HGF)0$$aGoerke, Steffen$$b6
000142103 7001_ $$0P:(DE-HGF)0$$aSchuenke, Patrick$$b7
000142103 7001_ $$aZaiss, Moritz$$b8
000142103 7001_ $$0P:(DE-He78)f4c0be14a7bb58948e5800ccdcbfe9bc$$aRegnery, Sebastian$$b9$$udkfz
000142103 7001_ $$0P:(DE-He78)d2d971750bce6217eb90fff9b01e61f9$$aBickelhaupt, Sebastian$$b10$$udkfz
000142103 7001_ $$0P:(DE-He78)4a14b13a372ab8bf853e4b650a6bd98a$$aBäumer, Philipp$$b11$$udkfz
000142103 7001_ $$aBendszus, Martin$$b12
000142103 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b13$$udkfz
000142103 7001_ $$aUnterberg, Andreas$$b14
000142103 7001_ $$0P:(DE-He78)29b2f01310f7022916255ddba2750f9b$$aBachert, Peter$$b15$$udkfz
000142103 7001_ $$0P:(DE-He78)022611a2317e4de40fd912e0a72293a8$$aLadd, Mark$$b16$$udkfz
000142103 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b17$$udkfz
000142103 7001_ $$0P:(DE-He78)77588f5b9413339755a66e739d316c7d$$aRadbruch, Alexander$$b18$$eLast author$$udkfz
000142103 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noy073$$gVol. 20, no. 12, p. 1661 - 1671$$n12$$p1661 - 1671$$tNeuro-Oncology$$v20$$x1523-5866$$y2018
000142103 909CO $$ooai:inrepo02.dkfz.de:142103$$pVDB
000142103 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000142103 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2017
000142103 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142103 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142103 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142103 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000142103 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142103 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142103 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142103 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000142103 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2017
000142103 9141_ $$y2018
000142103 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c6e31fb8f19e185e254174554a0cccfc$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000142103 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)98b696ed60c17f4ddd0da9fdc20a2492$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000142103 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7c89f57d41cbe565e6154bf1997b9178$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000142103 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000142103 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000142103 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)65fe7a46247e2ac4b15f194631c56cd1$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000142103 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000142103 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000142103 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f4c0be14a7bb58948e5800ccdcbfe9bc$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000142103 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d2d971750bce6217eb90fff9b01e61f9$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000142103 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4a14b13a372ab8bf853e4b650a6bd98a$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000142103 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000142103 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)29b2f01310f7022916255ddba2750f9b$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000142103 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)022611a2317e4de40fd912e0a72293a8$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000142103 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000142103 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)77588f5b9413339755a66e739d316c7d$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000142103 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000142103 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x0
000142103 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x1
000142103 9201_ $$0I:(DE-He78)E020-20160331$$kE020$$lMedizinische Physik in der Radiologie$$x2
000142103 9201_ $$0I:(DE-He78)G370-20160331$$kG370$$lKKE Neuroonkologie$$x3
000142103 9201_ $$0I:(DE-He78)E012-20160331$$kE012$$lNeuroonkologische Bildgebung$$x4
000142103 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x5
000142103 980__ $$ajournal
000142103 980__ $$aVDB
000142103 980__ $$aI:(DE-He78)E010-20160331
000142103 980__ $$aI:(DE-He78)G380-20160331
000142103 980__ $$aI:(DE-He78)E020-20160331
000142103 980__ $$aI:(DE-He78)G370-20160331
000142103 980__ $$aI:(DE-He78)E012-20160331
000142103 980__ $$aI:(DE-He78)L101-20160331
000142103 980__ $$aUNRESTRICTED